Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
Both therapies target previously treated non-small cell lung cancer (NSCLC) patients but focus on different genetic mutations. These updates were announced earlier this weekend at the European Society for Medical Oncology (ESMO) Congress 2024 meeting held in Spain. NUVL Boasts Encouraging Pipeline Potential in NSCLC Space Management presented updated data from the early-stage portions of two separate phase I/II studies — ARROS-1 and ALKOVE-1. While the ARROS-1 study evaluates zidesamtinib inpatients with advanced ROS1-positive NSCLC, the ALKOVE-1 study evaluates NVL-655 in patients with advanced ALK-positive NSCLC. Data from the ARROS-1 study showed that 44% of patients who received zidesamtinib responded to treatment. In the ALOVE-1 study, 38% of patients responded to treatment with NVL-655. Both studies involved patients whose cancers failed to respond to heavily pre-treated patients who had already been treated with Pfizer 's PFE Lorbrena or Bristol Myers ' BMY Augtyro. W
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.MarketBeat
- Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsPR Newswire
- Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $100.00 price target on the stock.MarketBeat
- Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $125.00. They now have an "overweight" rating on the stock.MarketBeat
- Nuvalent Announces Closing of Upsized Public Offering of Common StockPR Newswire
NUVL
Earnings
- 11/12/24 - Miss
NUVL
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- NUVL's page on the SEC website